You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: BIOLYTIC LAB PERFORMANCE, INC. Topic: 300
Summary RNA synthesis technologies have become critical in basic biomedical research and in development of RNA based sensors diagnostics and therapeutics Currently RNAs are synthesized by either solid phase phosphoramidite chemistry or by transcription in solution with phage encoded RNA polymerases The structural diversity of chemically synthesized RNAs is limited by the availa ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: NEONC TECHNOLOGIES INC Topic: BT
DESCRIPTION provided by applicant Glioblastoma multiforme GBM the most common and malignant of all gliomas has a median survival time of months Standard of care chemotherapy using temozolomide TMZ is effective initially but the GBM inevitably recurs and these recurrent tumors are resistant to TMZ There are currently no effective treatment options for patients with TMZ resistant ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: CAPRICOR, INC. Topic: NHLBI
DESCRIPTION provided by applicant One of the most complex forms of congenital heart disease hypoplastic left heart syndrome HLHS affects an average of in every newborns with a mortality rate of up to percent during the first year of life The overall goal f our research is to develop safe and effective ways to improve short term and long term survival rates in babies born with HL ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: TRELLIS BIOSCIENCE, INC. Topic: NIAID
DESCRIPTION provided by applicant About of serious bacterial infections are biofilm mediated Not only do biofilms provide an anchor and physical protection for bacterial cells but the physiology and genetic programming of bacteria also shifts between the planktonic free floating and sessile stationary states Most notably antibiotic sensitivity differs betwen the two states with ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: BioIncept, LLC Topic: NIAID
DESCRIPTION provided by applicant Recent nuclear accidents and threats have highlighted the growing risk of widespread radiation exposure causing a potentially devastating public health emergency Acute radiation syndrome ARS develops after total body or partial body irradiation at a moderate to high dose and is especially damaging to the immune system Damage to the skin gut and central n ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: ARISAN THERAPEUTICS INC Topic: NIAID
Project Summary Linking infectious agent diagnostics to clinical decision making at the point of care requires a fast highly sensitive and simple to use method that takes into account the infrastructure and workflow in clinical settings of both developing and developed regions In addition being able to distinguish among multiple potential infectious pathogens in a single test is of great impor ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Renova Therapeutics, Inc. Topic: NHLBI
DESCRIPTION provided by applicant Gene transfer for the treatment of cardiovascular diseases is bedeviled by inability to obtain safely and easily sufficient cardiac transgene expression Current methods of gene transfer for heart disease include intramuscular injection into heart muscle or intracoronary delivery approaches that are cumbersome to apply Consequently we have considered the u ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: DNATREK, LLC Topic: NIEHS
DESCRIPTION provided by applicant Science based strategies for quantifying and mitigating the impact of anthropogenic emissions on public health are essential for the sustainability of cities Similar strategies can also be used to develop and assess the effectiveness of a national defense system against terrorist attacks with airborne biological agents and protect against the spread of airborn ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
Use of EF2K inhibitors to inhibit tumor growth and sensitize cancer cells to existing chemotherapy treatmentSBC: LONGEVICA PHARMACEUTICALS, INC. Topic: 102
DESCRIPTION provided by applicant Eukaryotic elongation factor protein kinase eEF K is a ubiquitously expressed protein that belongs to a family of alpha kinases characterized by an andquot atypicalandquot kinase domain Our recent findings demonstrate that inhibition or genetic inactivation of eEF K protects normal tissues from cytotoxic effects of ionizing radiation and chemotherapeutic ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
Use of Highly Porous Polymer Beads to Remove Anti-A and Anti-B Antibodies from Plasma for TransfusionSBC: CYTOSORBENTS MEDICAL INC Topic: DHP15B001
The ready availability of universal donor plasma to rapidly treat massively bleeding hospital trauma patients and warfighters with combat casualties is a key element of current recommendations for trauma resuscitation, yet universal AB donor plasma is relSTTR Phase I 2016 Department of DefenseDefense Health Agency